Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tildrakizumab Phase 2b in Moderate-to-Severe Chronic Plaque Psoriasis
NCT01225731Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2010
- Primary completion
- Nov 2011
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, randomised, double-blind trial of tildrakizumab in plaque psoriasis (5 arms), sponsored by Merck & Co. Primary endpoints: Percentage of Participants With a Psoriasis Area and Severity Index (PASI) 75 Response at 16 weeks, Number of Participants Experiencing Adverse Events at 72 weeks and 1 more. Started Oct 2010; status: completed.
02
Drugs
tildrakizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT01225731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01225731.